Enriqueta Felip
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona
Spain
Enriqueta Felip holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and is currently Section Chief at the Vall d’Hebron University Hospital (HUVH), Head of the Vall d’ Hebron Institute of Oncology’s (VHIO) Thoracic Tumors Group.
Dr. Felip was Associate Professor at the UAB from 2010 to May 2019 and since March 2024 she is a full Professor of Medicine at the same university. She was also a Professor of Medicine at the Universitat de Vic (UVic-UCC) from 2020 – 2024.
Her research focuses on accelerating more effective, personalized and targeted cancer medicines matched to specific molecular alterations identified in patients, unmasking molecular mechanisms of acquired cancer drug resistance, and optimizing immune-based strategies in both advanced and early-stage non-small cell lung cancer.
Enriqueta Felip served as President (2021 – 2023) of the Spanish Society of Medical Oncology (SEOM), and was elected as a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) from 2017 to 2021. She has also been a member of the Educational and Scientific Committees of the European Society for Medical Oncology (ESMO), World Conference on Lung Cancer (WCLC), and European Lung Cancer Conference (ELCC).
Enriqueta Felip has also lent her expertise to several scientific organizations. These appointments have included Subject Editor of the Guidelines Working group ESMO Minimum Clinical Recommendations in lung cancer (2006 – 2014) and Coordinator of the 1st ESMO Consensus Conference on Lung Cancer. In 2015, she received the first ESMO Women for Oncology Award. Dr Felip was co-Chair of the IASLC 20th WCLC, in Barcelona in 2019. She is presently a member of the Scientific Committees of the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP).
Dr. Felip serves on the Editorial Boards of various top-tier journals including Annals of Oncology and the Journal of Thoracic Oncology. She has (co) authored approximately 400 peer-reviewed papers with an H-Index of 94.